Andrew C. Harris

Andrew C. Harris, MD

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics

Divisions:

Academic Office Information

Andrew.Harris@hsc.utah.edu

Board Certification

  • American Board of Pediatrics (Pediatrics)
  • American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Research Interests

  • Identification and Clinical Application of Graft-Versus-Host-Disease (GVHD) Biomarkers
  • Post-Bone Marrow Transplant (BMT) Relapse Prevention and Management

Dr. Harris’s academic career began at the University of Michigan when he joined the Pediatric Hematology-Oncology faculty in 2011 upon completing his fellowship there. While at Michigan, he helped identify novel plasma biomarkers of acute graft-versus-host disease (GVHD) and a biomarker-based staging system for GVHD that predicts non-relapse mortality following allogeneic stem cell transplantation. He also helped establish the guidelines for clinical GVHD data collection utilized by MAGIC, an international GVHD research consortium, and that have been adopted/endorsed by the Children’s Oncology Group (COG), the Center for International Blood and Marrow Transplant Research (CIBMTR), the National Institutes of Health (NIH), and the European Group for Blood and Marrow Transplantation (EBMT). His clinical interests include blood and marrow transplantation and cellular therapies for high-risk hematologic malignancies and hematology/immunologic disorders.

Dr. Harris’s research interests include the prediction, prevention and prognostication of acute GVHD through the use of biomarkers and the development of novel prevention and management strategies for this life-threatening complication of blood and marrow transplantation. He also has an interest in post-transplant treatment strategies to prevent relapse of high-risk leukemia.

He formerly served on the Biomarker Committee for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and is an active member in the CIBMTR Working Committees for Pediatric Cancer, Graft-versus-Host Disease and Regimen-Related Toxicity and Supportive Care. He has been the Principal Investigator or Co-Investigator of grants through the National Cancer Institute and Hyundai Hope on Wheels®.

Education History

Fellowship University of Michigan
 Fellow
Residency Cleveland Clinic Children’s Hospital
 Resident
Professional Medical Case Western Reserve University School of Medicine
 MD
Undergraduate Bowling Green State University
 BS

Selected Publications

Journal Article

  1. Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS (2021). Phase II Trial of Costimulation Blockade with Abatacept for Prevention of Acute GVHD. J Clin Oncol.
  2. Schultz KR, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, Azadpour S, Ostroumov E, Subrt P, Halevy A, Mostafavi S, Cuvelier GDE (2020). Immune Profile Differences between Chronic GvHD and Late Acute GvHD: Results of the ABLE/PBMTC 1202 Studies. Blood, 135(15), 1287-1298.
  3. Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, De Moerloose B, Davis KL, Nemecek E, Driscoll T, Mechinaud F, Boissel N, Rives S, Bader P, Peters C, Sabnis HS, Grupp SA, Yanik GA, Hiramatsu H, Stefanski HE, Rasouliyan L, Yi L, Shah S, Zhang J, Harris AC (2019). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol, 20(12), 1710-1718.
  4. Cuvelier GDE, Nemecek ER, Wahlstrom JT, Kitko CL, Lewis VA, Schechter T, Jacobsohn DA, Harris AC, Pulsipher MA, Bittencourt H, Choi SW, Caywood EH, Kasow KA, Bhatia M, Oshrine BR, Flower A, Chaudhury S, Coulter D, Chewning JH, Joyce M, Savaan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva AC, Lawitschka A, West LJ, Pan B, Al-Hamarneh YN, Halevy A, Schultz KR (2019). Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria. Blood, 134(3), 304-316.
  5. Zhao D, Kim YH, Jeong S, Greenson JK, Chaudhry MS, Hoepting M, Anderson ER, van den Brink MR, Peled JU, Gomes AL, Slingerland AE, Donovan MJ, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul AM, Lieu TC, Reddy P, Ferrara JL (2018). Survival signal REG3-α prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest, 128(11), 4745-5185.
  6. Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, OBrien T, Williams K, Pasquini MC, Levine JE (2018). Comparison of Pediatric Allogeneic Transplant Outcomes Using Myeloablative Busulfan with Cyclophosphamide or Fludarabine. Blood Adv, 2(11), 1198-1206.
  7. Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera EF, Hogan WJ, Wolfl M, Qayed M, Hexner EO, Wudhikarn K, Ordermann R, Young R, Shah J, Hartwell MJ, Chaudhry M, Aziz M, Etra A, Yanik GA, Kroger N, Weber D, Chen YB, Nakamura R, Rosler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Ozbek U, Ferrara JLM, Levine JE (2018). MAGIC Biomarkers Predict Long Term Outcomes for Steroid-Resistant Acute GVHD. Blood, 131(25), 2846-2855.
  8. Jacobsohn DA, Loken MR, Fei M, Adams A, Eidenschink-Brodersen L, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meschinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour Am Kasow KA, Gillia AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano J, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA (2018). Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia Pre- and Post-Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biol Blood Marrow Transplant, 24(10), 2040-2046.
  9. Miller HK, Braun TM, Stillwell T, Harris AC, Choi S, Connelly J, Couriel D, Goldstein S, Kitko CL, Magenau J, Pawarode A, Reddy P, Riwes M, Yanik GA, Levine JE (03/2017). Infectious Risk Following Allogeneic Hematopoietic Cell Transplant Complicated by Acute Graft-Versus-Host Disease. Biol Blood Marrow Transplant, 23(3), 522-528.
  10. Hartwell MJ, zbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wlfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Krger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rsler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL (2017). An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight, 2(3), e89798.
  11. Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer D, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW (04/2016). FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant, 51(4), 511-20.
  12. Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bonworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wlfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE (01/2016). International, multi-center standardization of acute graft-versus-host disease clinical data collection: a report from the MAGIC consortium. Biol Blood Marrow Transplant, 22(1), 4-10.
  13. Pawarode A, Mineishi S, Reddy P, Braun TM, Khaled YA, Choi SW, Magenau JM, Harris AC, Connelly JA, Kitko CL, Parkin BL, Goldstein SC, Yanik GA, Levine JE, Ferrara JL, Couriel DR (2016). Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant, 22(1), 54-60.
  14. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM (2015). Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA, 314(9), 913-925.
  15. Magenau JM, Braun T, Reddy P, Parkin B, Pawarode A, Mineishi S, Choi S, Levine J, Li Y, Yanik G, Kitko C, Churay T, Frame D, Riwes MM, Harris A, Bixby D, Couriel DR, Goldstein SC (2015). Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol, 94(6), 1033-41.
  16. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JL, Jones R, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini M, Socie G, Antin JH, Levine JE, Weisdorf DJ (2015). A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant, 21(4), 761-7.
  17. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Magenau J, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara LM (2015). A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol, 2(1), e21-e29.
  18. Gatza E, Braun T, Levine JE, Ferrara JL, Zhao S, Wang T, Chang L, Harris A, Pawarode A, Kitko C, Magenau JM, Yanik GA, Couriel DR, Goldstein S, Connelly J, Reddy P, Paczesny S, Choi SW (2014). Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 20(9), 1426-34.
  19. Levine JE, Huber E, Hammer ST, Harris AC, Greenson JK, Braun TM, Ferrara JL, Holler E (2013). Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood, 122(8), 1505-9.
  20. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S (2013). ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med, 369(6), 529-39.
  21. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, Mineishi S, Pawarode A, Yanik G, Levine JE (2013). Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica, 98(2), 179-84.
  22. Fiema B, Harris AC, Gomez A, Pongtornpipat P, Lamiman K, Vander Lugt MT, Paczesny S (2012). High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease.LID - 10.3791/4247 [doi]LID - 4247 [pii]. J Vis Exp, (68).
  23. Yanik GA, Mineishi S, Levine JE, Kitko CL, White ES, Vander Lugt MT, Harris AC, Braun T, Cooke KR (2012). Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 18(7), 1044-54.
  24. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S (2012). Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood, 119(12), 2960-3.
  25. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin A, Zhang Q, Hanash S, Paczesny S (2011). Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood, 118(25), 6702-8.
  26. Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, Kitko C, Choi S, Yanik G, Frame D, Harris A, Erba H, Kujawski L, Elenitoba-Johnson K, Sanks J, Jones D, Paczesny S, Ferrara J, Levine J, Mineishi S (2011). Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood, 118(15), 4258-64.

Review

  1. Levine JE, Hogan WJ, Harris AC, Litzow MR, Efebera YA, Devine SM, Reshef R, Ferrara JL (09/01/2014). Improved accuracy of acute graft-versus-host disease staging among multiple centers. [Review]. Best Pract Res Clin Haematol, 27(3-4), 283-287.
  2. Harris AC, Ferrara JL, Levine JE (2013). Advances in predicting acute GVHD. [Review]. Br J Haematol, 160(3), 288-302.
  3. Harris AC, Levine JE, Ferrara JL (2012). Have we made progress in the treatment of GVHD? [Review]. Best Pract Res Clin Haematol, 25(4), 473-8.

Book Chapter

  1. Harris AC, Levine JE (2014). Acute Graft-versus-host disease. In Abutalib S and Markman M (Eds.), Cancer Consult: Expertise for Clinical Practice (pp. 432-7). Hoboken, NJ: John Wiley & Sons Publishing.

Case Report

  1. Shyr DC, Homsombath AA, Chan PA, Boyer MA, Harris AC (2020). Using CD19 Chimeric Antigen Receptor-T Cell Therapy in a 4-Month-Old Patient with Infantile Acute Lymphoblastic Leukemia. Pediatr Blood Cancer, 67(4), e28155.

Letter

  1. Laetsch TW, Harris AC (2020). Immunoglobulin replacement and quality of life after CAR T-cell therapy (Authors' reply) [Letter to the editor]. Lancet Oncol, 21(1), e7.

Abstract

  1. Cuvelier GD, Kariminia A, Nemecek ER, Kitko CL, Wahlstrom JT, Harris AC, Bittencourt H, Lewis VA, Pulsipher MA, Schechter T, Choi SW, Caywood EH, Bhatia M, Kasow KA, Jacobsohn DA, Oshrine B, Chaudhury S, Chewning JH, Flower A, Coulter D, Joyce M, Savasan S, Pawlowska AB, Megason GC, Mitchell D, Cheerva A, Lawitschka A, Ng B, Schultz KR (2020). Naïve Helper T Cell and Regulatory T and NK Cell Subsets are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study.  [Abstract]. 136(Supplement 1), 11-12.
  2. Shah NN, OBrien MM, Yuan C, Ji L, Xu X, Rheingold SR, Bhojwani D, Uo J, Harris AC, Brown PA, Borowitz MJ, Devidas M, Raetz EA, Gore L, Loh ML (2020). Evaluation of CD22 Modulation as a Mechanism of Resistance to Inotuzumab Ozogamicin (InO): Results from Central CD22 Testing on the Children’s Oncology Group (COG) Phase 2 Trial of InO in Children and Young Adults with CD22+ B-Acute Lymphoblastic Leukemia (B-ALL) [Abstract].
  3. Grupp S, Hu ZH, Zhang Y, Keating A, Pulsipher MA, Philips C, Margossian SP, Rosenthal J, Salzberg D, Schiff DE, Yanik G, Curran KJ, Harris AC, Hematti P, Nikiforow S, Steinert P, Yi L, Chawla R, Horowitz MM, Bleickhardt E, Pasquini MC (2019). Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry [Abstract]. 134(S1), 2619.
  4. OBrien MM, Ji L, Rheingold SR, Bhojwani D, Yi J, Shah NN, Yuan C, Harris AC, Brown P, Borowitz M, Militano O, Frausto EG, Blank C, Devidas M, Gore L, Loh M (2019). A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children’s Oncology Group Protocol AALL1621 [Abstract]. 134(S1), 741.
  5. Qayed M, Watkins B, Bratrude B, Betz K, Rhodes J, Sinclair S, Suessmuth Y, Yu A, Dean C, Cribbin K, Narayan A, Hunt D, Schwartz N, Hebert K, Pasquini M, Rogatko A, Tighiouart M, Kim S, Bresee C, Gillespie S, Davis J, Choi S, Duncan C, Giller R, Grimley M, Harris A, Hacobsohn D, Lalefar N, Norkin M, Pulsipher M, Shenoy S, Petrovic A, Schultz K, Blazar B, Langston A, Horan J, Kean L (2019).  T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention in matched and mismatched unrelated donor transplantation: Results of the first phase 2 trial [Abstract]. 54(S1), 0100.
  6. Watkins BW, Qayed M, Bratrude B, Betz K, Sinclair S, Suessmuth Y, Rhodes J, Yu A, Cribbin K, Dean C, Narayan A, Hunt D, Schwartz N, Hebert K, Pasquini MC, Rogatko A, Tighiouart M, Kim S, Bresee C, Banks A, Gillespie S, Choi S, Davis JH, Duncan CN, Giller R, Grimley MS, Harris AC, Jacobsohn DA, Lalefar NR, Norkin M, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Blazar BR, Langston AA, Horan J, Kean LS (02/2019). T Cell Costimulation Blockade with CTLA4-Ig (Abatacept) for Acute Gvhd Prevention in HLA Matched and Mismatched Unrelated Donor Transplantation: Results of the First Phase 2 Trial [Abstract]. Biology of Blood and Marrow Transplantation, 25(3, Supplement), S51-S52.
  7. Baruchel A, Grupp SA, Rives S, Boyer MW, Bittencourt H, Bader P, Beuchner J, Laetsch TW, Myers GD, Qayed M, Pulsipher MA, De Moerloose B, Hiramatsu H, Yanik GA, Stefanski HE, Davis KL, Driscoll T, Nemecek E, Peters C, Cota M, Shah S, Zhang J, Harris AC (2018). Improvement of patient-reported quality of life following tisagenlecleucel infusion in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia [Abstract]. Haematologica, 2(S1), 61-62.
  8. Cuvelier GD, Nemecek E, Wahlstrom JT, Harris A, Pulsipher MA, Lewis V, Bittencourt H, Choi SW, Kitko CL, Caywood E, Bhatia M, Kasow KA, Jocobsohn J, Oshrine B, Kheradpour A, Chaudhury S, Chewning J, Schechter T, Flower A, Coulter D, Joyce M, Savasan S, Pawlowska A, Megason G, Mitchell D, Cheerva A, Karaminia A, Halevy A, Schultz KR (03/2018). Recent Thymic Emigrants and Tregs Expressing CD45RA and CD31 are Decreased at Day 100 and Prognostic for Chronic Graft-Versus-Host Disease in Children: Results from the Applied Biomarkers of Late Effects (ABLE) / Pediatric Blood and Marrow Transplant Consortium 1202 Study [Abstract]. Biology of Blood and Marrow Transplantation, 24(3), S114-S115.
  9. Zhao D, Kim YH, Greenson JK, Chaudhry MS, Hoepting M, Jeong S, Anderson ER, Harris AC, Levine JE, Ozbek U, Hooper LV, Stappenbeck TS, Ver Heul A, Lieu TC, Reddy P, Ferrara J (02/18). Regenerating Islet-Derived 3-Alpha (REG3A) Protects the Intestinal Stem Cell Niche to Control Acute Gastrointestinal Graft-Versus-Host Disease [Abstract]. Biology of Blood and Marrow Transplantaion, 24(3), S47-S48.
  10. Dietz AC, Grupp SA, Laetsch TW, Stefanski H, Myers GD, Bittencourt H, Buechner J, Nemecek ER, Martin PL, Hiramatsu H, Mechinaud F, Yanik GA, De Moerloose B, Wood PA, Rasouliyan L, Zhang Y, Thomas SK, Shah S, Harris A (2017). Patient-Reported Quality of Life (QOL) Following CTL019 in Pediatric and Young Adult Patients (pts) with Relapsed/Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL). [Abstract]. Journal of Clinical Oncology, 35(Suppl), 10523.
  11. Jacobsohn D, Loken M, Fei M, Adams A, Eidenschenk Brodersen L, Fritschle W, Logan B, Woo Ahn K, Shaw B, Kletzel M, Olszewski M, Kahn S, Keating A, Harris A, Teira P, Margossian S, Duerst R, Martin P, Boyer M, Nemecek E, Dvorak C, Petrovic A, Pulsipher M (2017). Minimal Residual Disease (MRD) pre‐ and post‐ HCT for children with AML is highly predictive of event‐free survival: A Pediatric Blood and Marrow Transplant Consortium Study. [Abstract]. Bone Marrow Transplantation, 52(S1), S371.
  12. Cuvelier GDE, Nemecek ER, Wahlstrom JT, Harris AC, Pulsipher MA, Lewis V, Bittencourt H, Choi SW, Kitko CL, Caywood E, Bhatia M, Kasow KA, Jacobsohn DA, Petrovic A, Kerhadpour A, Chaudhury S, Chewning JH, Schechter T, Abikoff C, Coulter DW, Joyce M, Savasan S, Pawlowska A, Megason G, Mitchell D, Cheerva A, Halevy A, Schultz KR (02/24/2017). Challenges with Diagnosing Pulmonary Chronic GVHD in Children as per the 2014 National Institutes of Health Consensus Criteria: Applied Biomarkers of Late Effects (ABLE)/Pediatric Blood and Marrow Transplant Consortium (PBMTC) 1202 Study [Abstract]. Biology of Blood and Marrow Transplantation, 23(3, Supplement), S74-S75.
  13. Watkins B, Qayed M, Bratrude B, Betz K, Brown M, Rhodes J, Sinclair S, Suessmuth Y, Yu A, Hebert K, Pasquini MC, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Pulsipher MA, Shenoy S, Blazar B, Langston A, Horan JT, Kean L (2017). T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-MisMatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival [Abstract]. Blood, 130(Suppl 1), 212.
  14. Laetsch TW, Maude SL, Grupp SA, Boyer M, Harris AC, Qayed M, Phillips CL, Pulsipher MA, Bittencourt H, Wood P, Mueller KT, Weng Y, June CH, Levine BL, Hiramatsu H (2017). CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome and Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia [Abstract]. Blood, 130(Suppl 1), 1280.
  15. Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak CC, Frangoul H, Freytes CO, Gale RP, Hong S, Lazarus HM, Mineishi S, Nishihori T, OBrien T, Williams KM, Pasquini MC, Levine JE (12/2016). Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children [Abstract]. Blood, 128(22), 664.
  16. Major-Monfried H, Ozbek U, Renteria AS, Hartwell MJ, Pawarode A, Yanik GA, Ayuk FA, Holler E, Efebera YA, Hogan WJ, Qayed M, Hexner EO, Wudhikarn K, Wolfl M, Ordemann R, Mielke S, Bonwoasate U, Devine SM, Kroeger N, Al-Malki M, Chin YB, Harris AC, Jagasia MH, Kitko CL, Litzow MR, Locatelli F, Nakamura R, Reddy PR, Reshef R, Roesler W, Weber D, Ferrara J, Levine JE (12/20016). Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinicl Response After One Week of Treatment [Abstract]. Blood, 128(22), 510.
  17. Hartwell MJ, Ozbek U, Holler E, Renteria AS, Reddy PR, Aziz M, Hogan WJ, Ayuk FA, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wolfl M, Mielke S, Pawarode A, Chen YB, Devine SM, Harris AC, Jagasia MH, Kitko CL, Litzow MR, Kroeger N, Locatelli F, Nakamura R, Reshef R, Roesler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JLM (12/2016). An Early Biomarker Algorithm Predicts Lethal Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation [Abstract]. Blood, 128(22), 509.
  18. Harris AC, Young R, Devine SM, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebara YA, Holler E, Litzow MR, Ordemann R, Qayed M, Renteria AS, Reshef R, Wolfl M, Chen YB, Goldstein S, Jagasia MH, Locatelli F, Miledke S, Porter DL, Schechter T, Shekhovtsova Z, Ferrara JLM, Levine JE (12/3/2015). Guidelines for the Standardization of Acute Graft-Versus-Host Disease Clinical Data Collection: An International Consensus Report [Abstract]. Blood, 126(23), 3154.
  19. Harris AC, Braun T, Byersdorfer CA, Choi SW, Connelly JA, Kitko CL, Yanik G, Levine J (2015). Fludarabine combined with myeloablative busulfan (FluBu4) results in reliable engraftment and low transplant-related mortality in pediatric patients [Abstract]. Biol Blood Marrow Transplant, 21(2, Suppl), S223-4.
  20. MacMillan ML, Robin M, Harris AC, Defor TE, Martin PJ, Alousi A, Ho VT, Bolanos-Meade J, Ferrara JLM, Jones RJ, Arora M, Blazar BR, Holtan SG, Jacobsohn D, Pasquini MC, Socie G, Antin JH, Levine JE, Weisdorf DJ (2014). A refined clinical risk score at onset of treatment for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality; also presented orally at American Society of Hematolgy Annual Meeting, San Francisco, CA [Abstract]. Blood, 124(21), 188.
  21. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller HK, Magenau JM, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara JLM (2014). A biomarker algorithm defines onset grades of acute graft-vs-host disease with distinct non-relapse mortality; also presented orally at American Society of Hematolgy Annual Meeting, San Francisco, CA [Abstract]. Blood, 124(21), 661.
  22. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, Maganau J, Weisdorf DJ, Ho VT, Bolanos-Meade J, Alousi AM, Ferrara JLM, Blood and Marrow Transplant Clinical Trials Network (2014). A new Ann Arbor Grading System uses biomarkers to risk stratify patients for non relapse mortality and the onset of acute graft versus host disease; also presented orally at 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy [Abstract]. Biol Blood Marrow Transplant, 49(1, Supplemental), S3-4.
  23. Magenau J, Westervelt P, McGuirk JP, Khaled SK, Jagasia MH, Rowley S, Kim D, Frey NV, Parameswaran H, Lieland S, Braun T, Schechter-Finkelstein T, Parkin B, Harris AC, Scott BL, DiPersia JF, Forman SJ, Mineishi S (2014). Preliminary data from a multi-center study of clofarabine/busulfan conditioning for acute myeloid leukemia not in remission at allogeneic transplantation [Abstract]. Biol Blood Marrow Transplant, 20(2, Suppl), S155-6.
  24. Levine JE, Harris AC, Taylor A, Braun TM, Magenau J, Ferrara JLM (2013). A biomarker-based grading system at onset of GVHD predicts NRM better than the modified Glucksberg grading system; also presented orally at American Society of Hematology Annual Meeting, New Orleans, LA [Abstract]. Blood, 122(21), 145.
  25. Gomez A, Hammer SG, Braun T, Hanash S, Ferrara JLM, Greenson JK, Wang H, Zhang Q, Vander Lugt M, Pongtornpipat P, Mamiman K, Conlon M, Chang L, Choi SW, Levine JE, Harris A, Couriel DR, Reddy P, Paczesny P (2013). A novel CD4+CD146+CCR5+ T-cell population is a biomarker of intestinal graft-versus-host disease; also presented orally at 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, UK [Abstract]. Bone Marrow Transpl, 48(2, Supplemental), S66.
  26. Vander Lugt MT, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Paczesny S (2013). Plasma ST2 concentrations predict acute GVHD development and non-relapse mortality; also presented orally at BMT Tandem Meetings, Salt Lake City, UT [Abstract]. Biol Blood Marrow Transplant, 19(2, Supplemental), S142-3.
  27. Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi SW, Kitko C, Goldstein S, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly J, Byersdorfer C, Levine JE (2013). A combination of clinical characteristics and day 7 biomarker concentrations predicts GVHD following hematopoietic cell transplantation from related donors; also presented orally at BMT Tandem Meetings, Salt Lake City, UT [Abstract]. Biol Blood Marrow Transplant, 19(2, Supplemental), S138-9.
  28. Magenau J, Pawarode A, Couriel DR, Yanik G, Mineishi S, Braun T, Reddy P, Ferrara JLM, Frame D, Choi SW, Harris AC, Kitko CL, Connelly JA, Levine J, Goldstein SC (2013). Impact of dose intensification of FluBu2 to FluBu4 on transplant related mortality, relapse, and survival after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia in Remission [Abstract]. Biol Blood Marrow Transplant, 19(2, Supplement), S226.
  29. Pawarode A, Mineishi S, Braun T, Ferrara JLM, Magenau J, Peres E, Yanik G, Reddy P, Levine JE, Choi SW, Kitko CL, Harris AC, Connelly JA, Goldstein SC, Couriel D (2013). Phase 2 study of allogeneic hematopoietic cell transplant (HCT) following intermediate-intensity fludarabine and busulfan X 4 (FluBu4) conditioning for high-risk or advanced multiple myeloma [Abstract]. Biol Blood Marrow Transplant, 19(2, Supplement), S238.
  30. Harris AC, Ferrara JLM, Braun T, Couriel DR, Choi SW, Kitko C, Goldstein S, Magenau J, Paczesny S, Pawarode A, Reddy P, Yanik G, Taylor A, Connelly J, Byersdorfer C, Levine JE (2012). An algorithm combining clinical characteristics and day 7 biomarker concentrations predicts future GVHD following related donor hematopoietic cell transplantation; also presented orally at American Society of Hematology Annual Meeting, Atlanta, GA [Abstract]. Blood, 120(21), 463.
  31. Vander Lugt MT, Braun TM, Hanash S, Ferrara JLM, Ritz J, Ho VT, Antin JH, Zhang Q, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Paczesny S (2012). Plasma ST2 concentrations predict development of acute GVHD and non-relapse mortality; also presented orally at American Society of Hematology Annual Meeting, Atlanta, GA [Abstract]. Blood, 120(21), 466.
  32. Vander Lugt M, Braun T, Ferrara J, Hanash S, Levine J, Harris A, Couriel D, Paczesny S (2012). Plasma ST2 predicts therapy-resistant graft-versus-host disease and survival; also presented orally at American Association of Immunologists Annual Meeting 2012, Boston, MA [Abstract]. J Immunol, 188, 126.13.
  33. Vander Lugt MT, Braun TM, Ferrara JLM, Hanash S, Levine JE, Wang CH, Zhang Q, Chin A, Harris AC, Choi SW, Couriel D, Reddy P, Paczesny S (2012). Plasma concentration of suppressor of tumorigenicity 2 (ST2), the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment [Abstract]. Biol Blood Marrow Transplant, 18(2, Supplement), S201-2.
  34. Vander Lugt MT, Braun T, Ferrara JLM, Hanash S, Levine J, Wang C, Zhang Q, Chin A, Harris AC, Choi SW, Couriel D, Reddy P, Paczesny S (2011). Plasma concentration of ST2, the IL33 receptor, at initiation of graft versus host disease therapy predicts day 28 response and day 180 survival post-treatment; also presented orally at American Society of Hematology Annual Meeting, San Diego, CA [Abstract]. Blood, 118(21), 152.
  35. Harris AC, Ferrara JLM, Greenson JK, Braun TM, Holler E, Teshima T, Levine JE, Choi SW, Huber E, Landfried K, Vander Lugt M, Reddy P, Zhang Q, Hanash S, Paczesny S (2011). A novel grading system of lower Gastrointestinal acute graft-versus-host disease at disease onset predicts response to therapy and non-relapse mortality; also presented orally at American Society of Hematology Annual Meeting, San Diego, CA [Abstract]. Blood, 118(21), 153.
  36. Harris A, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q, Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E, Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S (2011). REG3α is a biomarker of gastrointestinal graft-versus-host disease [Abstract]. Central Society for Clinical Research/Midwest American Federation for Medical Research Regional Meeting, Chicago, IL.
  37. Harris AC, Ferrara JLM, Levine JE, Braun T, Hogan J, Crawford J, Pitteri S, Wang H, Chin A, Zhang Q, Granger J, Vander Lugt M, Byersdorfer C, Magenau J, Gomez A, Choi S, Kitko C, Yanik G, Peres E, Pawarode A, Mineishi S, Reddy P, Couriel DR, Hanash S, Paczesny S (2011). REG3α is a biomarker of gastrointestinal graft-versus-host disease [Abstract]. Biol Blood Marrow Transplant, 17(2, Supplement), S163-4.
  38. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi SW, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel DR, Reddy P, Hanash S, Ferrara JLM, Levine JE (2011). A three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease [Abstract]. Biol Blood Marrow Transplant, 17(2, Supplement), S167.
  39. Paczesny S, Braun T, Vander Lugt M, Harris A, Fiema B, Hernandez J, Choi SW, Kitko C, Magenau J, Yanik G, Peres EM, Pawarode A, Mineishi S, Whitfield J, Jones D, Couriel DR, Reddy P, Hanash S, Ferrara JLM, Levine JE (2010). Three biomarker panel at days 7 and 14 can predict development of grade II-IV acute graft-versus-host disease; abstract presented orally at American Society of Hematology Annual Meeting, Orlando, FL [Abstract]. Blood, 116(21), 675.
  40. Kitko CL, Mineishi S, Braun T, Choi SW, Jones D, Harris A, Khaled Y, Krijanovski O, Paczesny S, Peres E, Yanik G, Whitfield J, Ferrara JL, Levine JE (2009). Day7 TNFR1 levels following reduced intensity allogeneic hematopoietic stem cell transplant (HCT) predict for acute GVHD [Abstract]. Biol Blood Marrow Transplant, 15(2, Suppl), S129.